Key Takeaways
Edison Scientific will deploy Kosmos, its AI scientist, across the company-creation pipeline at Population Health Partners.
PHP is the firm behind Metsera, acquired by Pfizer in a deal worth up to $10 billion, and The Medicines Company, bought by Novartis for $9.7 billion.
The two plan to co-build biotechs for population-scale diseases, starting with a clinical-stage asset that could reach 10 percent of the world.
Edison Scientific is putting its artificial-intelligence scientist to work building new drug companies, through a partnership with the team behind some of the biggest biotech exits of the past decade.
Under the deal, announced June 29, Edison will deploy Kosmos, the system it calls an AI scientist, across the company-creation pipeline at Population Health Partners. PHP is the firm behind Metsera, the obesity company Pfizer agreed to buy in a deal worth up to $10 billion, and The Medicines Company, which Novartis bought for $9.7 billion. The two plan to co-build biotechs aimed at diseases that affect the largest share of the population, as STAT reported, starting in cardiovascular, inflammatory lung, and gastrointestinal disease.
From discovery to filings
The companies say they will start with an advanced clinical-stage asset already in PHP's portfolio, one with the potential to reach 10 percent of the world's population. Beyond discovery, Edison and PHP are building an AI workflow, powered by Kosmos, to help author the regulatory filings that move a drug toward trials, including the investigational new drug submissions that gate human testing.
The bet is that an AI scientist can compress the slow early steps of drug development, where most new medicines begin inside small companies rather than big pharma. Edison, a spinout that has also signed research deals with Incyte and Google DeepMind, is wagering that the same system can both find candidates and help launch the companies around them. It fits a run of AI-for-biology work WYDE has covered, from Tessel Bio's generative chemistry model to the $500 million Intercept fund against respiratory viruses. Worth watching.
People Also Ask
What is Kosmos?
Kosmos is Edison Scientific's AI scientist, a system designed to run scientific analysis and discovery. Edison will deploy it across Population Health Partners' company-creation pipeline.
Who is Population Health Partners?
PHP is the firm behind Metsera, acquired by Pfizer in a deal worth up to $10 billion, and The Medicines Company, acquired by Novartis for $9.7 billion.
What diseases will the partnership target?
The two plan to build biotechs focused on cardiovascular, inflammatory lung, and gastrointestinal disease, starting with a clinical-stage asset that could reach 10 percent of the world's population.
How does AI fit into drug approvals?
Edison and PHP are building a Kosmos-powered workflow to help author regulatory filings, including the investigational new drug submissions required before human trials.